End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.3 CNY | +0.45% | -4.73% | +58.33% |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+58.33% | 4.09B | - | ||
+40.73% | 739B | C+ | ||
+32.83% | 598B | B | ||
-6.30% | 353B | C+ | ||
+15.15% | 318B | B- | ||
+4.05% | 285B | C+ | ||
+15.00% | 240B | B+ | ||
+9.78% | 210B | B- | ||
-5.52% | 206B | A+ | ||
+6.17% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301301 Stock
- Ratings Yili Chuanning Biotechnology Co.,Ltd.